Results for this period
Full year1 October 2025 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Sales of new women's healthcare drugs, biosimilars, and hematology and gastroenterology products increased, and the resulting increase in gross profit driven by higher revenue contributed to operating profit. However, the company recognized a valuation loss on investment securities and an impairment loss on long-term advance payments.
No matters to report
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 October 2025 to 30 September 2026 |
| Net Sales | 62,386 Millions of yen (YoY +20.7%) |
| Operating profit | 6,355 Millions of yen (YoY +27.4%) |
| Ordinary income | 6,176 Millions of yen (YoY +38.5%) |
| Profit attributable to owners of the parent | 2,831 Millions of yen (YoY -5.6%) |
| Net income per share | ¥111.18 |
| Operating Margin | 10.2 |
| Equity ratio | End of the current fiscal period 53.4 / End of previous period 50.2 |
| Total assets | 98,287 Millions of yen |
| Net assets | 52,451 Millions of yen |
| Cash flows from operating activities | 6,174 Millions of yen |
| Cash flows from investing activities | -3,630 Millions of yen |
| Cash flows from financing activities | -429 Millions of yen |
| Cash and cash equivalents at end of period | 9,496 Millions of yen |
| Full-year earnings forecast | Net Sales 69,190 Millions of yen (YoY +10.9%) / Operating profit 7,420 Millions of yen (YoY +16.8%) / Ordinary income 6,910 Millions of yen (YoY +11.9%) / Net income 4,880 Millions of yen (YoY +72.4%) |
| Annual Dividend Forecast | 52 Yen → 58.5 Yen（+12.5%） |
| Payout ratio | 46.8 |
| Shareholder Return Policy | The company has adopted a progressive dividend policy and intends to maintain a dividend payout ratio of at least 30%, excluding extraordinary factors. |
| Depreciation and amortization | 4,207 Millions of yen |
| Impairment loss | 762 Millions of yen |
| Breakdown of extraordinary income (loss) | Impairment loss 762 Millions of yen, Reduction of Fixed Asset Cost 258 Millions of yen, Valuation loss on investment securities 2,000 Millions of yen |
| Disclosure regarding the going concern assumption | No matters to report |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name Not applicable |
| Material subsequent events | Not applicable |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 26,541,100 |
| Treasury Shares at Period-End | 421,339 |
| Factors Behind Changes in Business Performance | Sales of new women's healthcare drugs, biosimilars, and hematology and gastroenterology products increased, and the resulting increase in gross profit driven by higher revenue contributed to operating profit. However, the company recognized a valuation loss on investment securities and an impairment loss on long-term advance payments. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales of new women's healthcare drugs, biosimilars, and hematology and gastroenterology products increased, and the resulting increase in gross profit driven by higher revenue lifted operating profit. However, net income attributable to owners of the parent declined because the company recognized a valuation loss on investment securities and an impairment loss on long-term advance payments.